Indication: It is suitable for the treatment of patients with B-cell chronic lymphocytic leukemia (CLL) who have received at least one standard alkylating agent regimen, but whose condition has not improved or continues to progress during or after treatment. Reference: It is used for the treatment of B-cell chronic lymphocytic leukemia (CLL), and is suitable for patients whose condition has not responded to a standard dosing regimen containing alkylating agents or whose condition has worsened, with an overall effective rate of 32% to 48%. Fudahua Tablets (Fludarabine Phosphate Tablets) can also be used to treat leukemia and lymphoma, but it is not effective for solid tumors such as breast cancer, colon cancer, non-small cell lung cancer, and head and neck cancer.